NCT02668172View on ClinicalTrials.gov

Pasireotide LAR and Pegvisomant Study in Acromegaly

PHASE4UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

March 31, 2017

Study Completion Date

June 30, 2017

Conditions
Acromegaly
Interventions
DRUG

Pasireotide LAR 60 mg

as mono-therapy or in combination with pegvisomant

DRUG

Pegvisomant

only in combination with pasireotide LAR

Trial Locations (1)

3000CA

Erasmus Medical Center, Rotterdam

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Erasmus Medical Center

OTHER